Aegis Says FDA's Outlook 'Not As Negative As People Think' on Amarin

The outlook of Amarin shares appeared bleak following an FDA release over concerns of the Vascepa drug. On October 16, an advisory committee will convene to decide if Amarin's lead drug will help with the treatment of mixed dyslipidemia. On Monday, Aegis Capital released a statement expressing their Buy rating, despite